AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

News provided by

Nov 06, 2022, 18:41 ET

SUZHOU, China and ROCKVILLE, Md., Nov. 6, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has released results from a Phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB), in an oral presentation at the 73^rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world's first clinical study reporting favorable safety and preliminary efficacy of an IAP antagonist for the treatment of patients with CHB.

Data from this clinical study suggest that APG-1387 has anti-hepatitis B virus (HBV) activity at doses of 12 mg and 30 mg, and synergistic effects when combined with sequential nucleos(t)ide analogue (NA) treatment. These data provide additional rationale for the continued development of APG-1387 in combination with other agents for the functional cure of CHB.

HBV infection is a global public health threat. The World Health Organization (WHO) estimates that approximately 300 million people worldwide are living with hepatitis B and 1.1 million deaths occur annually due to hepatitis B, hepatitis C, and their effects including liver cancer, cirrhosis, and other conditions caused by chronic viral hepatitis¹. In China, the surface antigen of the hepatitis B virus (HBsAg) is present in 5%-6% of the population, and there are approximately 70 million patients with chronic HBV infections the country, of whom 20-30 million have CHB². A total of 77% of liver cirrhosis cases and 84% of all primary hepatocellular carcinoma cases are associated with HBV infections³. Current guidelines recommend entecavir, tenofovir, tenofovir alafenamide, and long-acting interferon as standard anti-HBV treatments. However, only a small percentage of the patients who receive long-term treatment with these therapies can achieve HBsAg negativity and continued immune response after treatment. Majority of the patients require prolonged or even lifetime treatment, thus presenting an enormous unmet medical need for safe and effective therapies that can minimize the risk of disease progression and achieve functional cure with a relatively short duration of treatment.

Discovered and developed by Ascentage Pharma with global intellectual property rights, APG-1387 is a potent and highly selective next-generation IAP antagonist that has already shown anti-HBV potential in preclinical studies. Currently, the drug candidate is being evaluated in a Phase II study for the treatment of patients with CHB in China. APG-1387 can induce apoptosis (programmed death in diseased cells) and confer immune modulation in HBV-infected liver cells, and has the potential as a novel therapeutic for the functional cure of CHB.

Prof. Jinlin Hou, Director of the Center for Liver Diseases and the Institute of Hepatology at the Southern Medical University Affiliated Nanfang Hospital and the principal investigator of the study, commented, "At present, research on novel agents targeting the HBV and its host targets is in full swing, while the functional cure of CHB remains a major challenge globally. As the principal investigator of this Phase Ib study of APG-1387 in patients with CHB, I am glad that results from the study have been selected for an oral presentation at this year's AASLD Annual Meeting. These results show that a short-term treatment with APG-1387 can stimulate immune factors with clear anti-HBV activities, and has synergistic effects in combination with sequential NA treatment. The existing safety and efficacy data suggest that combining APG-1387 with other targeted drugs is a promising therapeutic approach worth further studies."

Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "Our pioneering work in evaluating IAP inhibitors for the treatment of CHB may bring a much-needed change to the current treatment landscape. Data presented at this year's AASLD Annual Meeting showed the preliminary efficacy and manageable safety of APG-1387, signaling the drug candidate's therapeutic potential in CHB. Moving forward, we will press ahead with the clinical development of APG-1387 in efforts to bring a new treatment option to patients with CHB in China and around the world."

Details of the oral presentation on APG-1387 at AASLD 2022 are as follows:
First-in-Human Study of APG-1387, Targeting Inhibitor of Apoptosis Proteins, For the Treatment of Patients with Chronic Hepatitis B

Abstract: #32
Session: Session 2 – Novel Therapies for the Functional Cure of CHB and CHC

Highlights:

Investigational agent APG-1387 is a bivalent antagonist of IAPs that may enhance HBV-specific T-cell response and induce apoptosis of hepatocytes expressing HBV antigen.
This study is the first to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of APG-1387 in Chinese patients with CHB.
Treatment-naïve patients received 4 weekly doses of APG-1387 intravenously at escalating dose levels (7, 12, 20, and 30 mg), followed by a 12-week observation period. Nucleos(t)ide analogue (NA) treatment was initiated per clinical guidelines during follow-up.
A total of 49 patients were enrolled, with a median age of 31 years, including 33 males and 29 patients who were HBeAg positive. Median (range) HBV DNA and HBsAg levels at baseline were 7.07 (4.59-8.87) log₁₀ IU/mL and 3.91 (2.64-5.27) log₁₀ IU/mL, respectively. During the observation period, 14 patients received NA and were classified as the sequential NA group, while the remaining 35 patients were classified as the monotherapy group; there were no significant differences in baseline characteristics between the two groups.
PK analysis indicated a dose-proportional increase in plasma exposure from 7 to 30 mg. The mean terminal half-life ranged from 3.01 hours to 5.17 hours and no drug accumulation was observed after multiple dosing.
A total of 30 patients experienced adverse events (AEs) considered to be related to the study treatment; the most prevalent AEs were transient alanine transaminase (ALT)/aspartate transaminase (AST) elevation (9/49 [18.4%]) and reversible Bell's palsy (7/49 [14.3%]).

Results of virological response:

On Day 28, HBV DNA, HBsAg, and HBeAg decreased significantly from baseline in the 12 mg and 30 mg groups, with median (range) decreases of -0.38 (-2.02 to 0.09) and -0.38 (-1.13 to 0.39) log10 IU/mL, -0.14 (-0.71 to 0.14) and -0.04 (-0.79 to 0.09) log10 IU/mL, and -0.06 (-0.41 to 0.01) and-0.04 (-0.42 to 0.03) log10 signal to cut-off (S/CO), respectively.
On Day 112, median (range) decreases from baseline in HBV DNA, HBsAg, and HBeAg were -0.18 (-3.16 to 0.81) and -4.69 (-6.46 to -2.51) log10 IU/mL, 0.02 (-1.06 to 0.38) and 0.02 (-1.06 to 0.38) log10 IU/mL, and -0.03 (-2.34 to 0.10) and -1.73 (-2.49 to -0.04) log10 S/CO in monotherapy and sequential NA groups, respectively.
On Day 112, HBV DNA, HBsAg, and HBeAg decreased to a significantly greater amount in the sequential group than in the monotherapy group. (p < 0.05).
Multiple regression analysis showed that baseline HBeAg positivity, ALT flare, and sequential NA treatment were independent factors for HBsAg > 0.5 log10 IU/mL.
IL-12 increased in a dose-dependent manner, and the other cytokines, including IFN-γ, IL-2Rα, and MCP-1, increased at 24 hours after the first dose of APG-1387, suggesting an immunomodulatory function for APG-1387.

Conclusions:

APG-1387 treatment in patients with CHB is generally safe and tolerable.
Exposure (AUC and Cmax) increased dose proportionally over the range from 7 to 30 mg, and no significant accumulation was seen after multiple dosing.
APG-1387 showed significant anti-HBV effect at doses of 12 and 30 mg, and sustained antiviral effect after discontinuation, including even a synergistic effect when combined with sequential NA treatment.
After treatment with APG-1387, the study observed increases in apoptotic biomarkers M30/M65 and cytokines such as IL-12 and IFN-γ, suggesting that APG-1387 has dual mechanisms of inducing apoptosis and immune modulation.
These preliminary safety and efficacy data support continued development of APG-1387 in combination with other agents towards a functional cure of chronic HBV infection. A Phase II study of APG-1387 in combination with entecavir is ongoing (NCT04568265).

References:

WHO Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Available at: https://www.who.int/publications/i/item/9789240027077
Liu, J., et al., Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ, 2019. 97(3): p. 230-238.
Chinese Society of Infectious Diseases and Chinese Society of Hepatology, Chinese Medical Association, Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 version). Chin J Clin Infect Dis, 2019. 12(6): p. 401-428

About Ascentage Pharma
Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 phase 1/2 clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA. A New Drug Application (NDA) for HQP1351 has been submitted and subsequently granted Priority Review status and a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) in China. To date, Ascentage Pharma has obtained a total of 12 ODDs from the US FDA for four of the company's investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

SOURCE Ascentage Pharma